News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myriad Genetics, Inc. (MYGN) Wins Gene Patent Ruling From US Appeals Court


8/17/2012 7:16:12 AM

A federal appeals court reaffirmed on Thursday the right of Myriad Genetics to patent two genes linked to breast and ovarian cancer, after the Supreme Court told it to take another look at the hotly contested case. A panel of the United States Court of Appeals for the District of Columbia Circuit upheld Myriad’s right to patent “isolated” genes known as BRCA1 and BRCA2, which account for most inherited forms of breast and ovarian cancer. But the court denied the biotechnology company’s effort to patent methods of “comparing” or “analyzing” DNA sequences.

Read at New York Times
Read at Reuters
Read at BBC News
Read at Forbes
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES